Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects

[1]  Bing Wang,et al.  IL‐16 regulates macrophage polarization as a target gene of mir‐145‐3p , 2019, Molecular immunology.

[2]  M. Panteghini,et al.  Making new biomarkers a reality: the case of serum human epididymis protein 4 , 2018, Clinical chemistry and laboratory medicine.

[3]  F. D’Acquisto,et al.  Repetitive Exposure of IL-17 Into the Murine Air Pouch Favors the Recruitment of Inflammatory Monocytes and the Release of IL-16 and TREM-1 in the Inflammatory Fluids , 2018, Front. Immunol..

[4]  L. Zerbini,et al.  The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview , 2018, Cells.

[5]  A. Gottlieb,et al.  Apremilast in Combination With an Interleukin 17A Inhibitor in the Treatment of Recalcitrant Palmoplantar Psoriasis , 2018, Journal of Psoriasis and Psoriatic Arthritis.

[6]  S. Mostafaei,et al.  Increased inflammatory responsiveness of peripheral blood mononuclear cells (PBMCs) to in vitro NOD2 ligand stimulation in patients with ankylosing spondylitis , 2018, Immunopharmacology and immunotoxicology.

[7]  J. Krueger,et al.  Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. , 2018, The Journal of allergy and clinical immunology.

[8]  L. French,et al.  Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis. , 2018, Journal of drugs in dermatology : JDD.

[9]  D. Veale,et al.  The pathogenesis of psoriatic arthritis , 2018, The Lancet.

[10]  M. Dougados,et al.  Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis , 2018, Annals of the rheumatic diseases.

[11]  S. Georgescu,et al.  The Pathophysiological Mechanisms and the Quest for Biomarkers in Psoriasis, a Stress-Related Skin Disease , 2018, Disease markers.

[12]  D. Cho,et al.  Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis , 2017, International journal of molecular sciences.

[13]  M. Brown,et al.  Progress of genome-wide association studies of ankylosing spondylitis , 2017, Clinical & translational immunology.

[14]  A. Dattola,et al.  The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins , 2017, Scientific Reports.

[15]  M. Cassatella,et al.  Human Neutrophils Produce CCL23 in Response to Various TLR-Agonists and TNFα , 2017, Front. Cell. Infect. Microbiol..

[16]  D. Foell,et al.  Proinflammatory Cytokine Environments Can Drive Interleukin‐17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis , 2017, Arthritis & rheumatology.

[17]  Jia Li,et al.  Therapeutic effects of human adipose tissue-derived stem cell (hADSC) transplantation on experimental autoimmune encephalomyelitis (EAE) mice , 2017, Scientific Reports.

[18]  G. Hong,et al.  Growth Arrest-Specific 6 Enhances the Suppressive Function of CD4+CD25+ Regulatory T Cells Mainly through Axl Receptor , 2017, Mediators of inflammation.

[19]  Michael F. Ochs,et al.  PatternMarkers & GWCoGAPS for novel data-driven biomarkers via whole transcriptome NMF , 2016, bioRxiv.

[20]  D. Gladman,et al.  Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis , 2016, Arthritis & rheumatology.

[21]  A. Chhabra,et al.  Ankylosing Spondylitis and Axial Spondyloarthritis. , 2016, The New England journal of medicine.

[22]  C. Selmi,et al.  Biomarkers in psoriatic arthritis: a systematic literature review , 2016, Expert review of clinical immunology.

[23]  G. Girolomoni,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) , 2015, The British journal of dermatology.

[24]  J. O'dell,et al.  The ongoing quest for biomarkers in Ankylosing Spondylitis , 2015, International journal of rheumatic diseases.

[25]  P. Barnes,et al.  Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells , 2015, PloS one.

[26]  G. Chodorowska,et al.  The Assessment of Selected Bone and Cartilage Biomarkers in Psoriatic Patients from Poland , 2015, Mediators of inflammation.

[27]  Peng-Yu Chen,et al.  The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1) , 2015, Journal of immunology research.

[28]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[29]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[30]  Jilly F. Evans,et al.  Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. , 2014, Cellular signalling.

[31]  D. Gladman,et al.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.

[32]  Hee-Jin Kim,et al.  Erythropoietin modulates the immune-inflammatory response of a SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS) , 2014, Neuroscience Letters.

[33]  J. Ho,et al.  Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma , 2013, Arthritis Research & Therapy.

[34]  L. Skov,et al.  Plasma YKL‐40: a potential biomarker for psoriatic arthritis? , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[35]  P. Schafer.  Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. , 2012, Biochemical pharmacology.

[36]  V. Chandran,et al.  Update on Biomarkers in Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting , 2012, The Journal of Rheumatology.

[37]  H. Kaplan,et al.  Retinal Self-Antigen Induces a Predominantly Th1 Effector Response in Axl and Mertk Double-Knockout Mice , 2011, The Journal of Immunology.

[38]  David R. Willé,et al.  Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. , 2011, Pharmacological research.

[39]  W. Liao,et al.  Which Psoriasis Patients Develop Psoriatic Arthritis? , 2010, Psoriasis forum.

[40]  Jie Ding,et al.  CoGAPS: an R/C++ package to identify patterns and biological process activity in transcriptomic data , 2010, Bioinform..

[41]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[42]  Lei Wu,et al.  Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis , 2010, British journal of pharmacology.

[43]  R. Flavell,et al.  Regulating human Th17 cells via differential expression of IL-1 receptor. , 2010, Blood.

[44]  J. Kelly,et al.  Identification of secreted proteins regulated by cAMP in glioblastoma cells using glycopeptide capture and label‐free quantification , 2009, Proteomics.

[45]  K. Wittkowski,et al.  Identification of Cellular Pathways of “Type 1,” Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis1 , 2008, The Journal of Immunology.

[46]  W. Alkema,et al.  Literature-based compound profiling: application to toxicogenomics. , 2007, Pharmacogenomics.

[47]  E. Diamandis,et al.  Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients , 2007, Experimental dermatology.

[48]  S.E. Chang,et al.  Neuropeptides and their receptors in psoriatic skin in relation to pruritus , 2007, The British journal of dermatology.

[49]  C. Günther,et al.  CCL23 Expression Is Induced by IL-4 in a STAT6-Dependent Fashion , 2007, The Journal of Immunology.

[50]  B. Nakken,et al.  Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. , 2007, Rheumatology.

[51]  Guoli Wang,et al.  LS-NMF: A modified non-negative matrix factorization algorithm utilizing uncertainty estimates , 2006, BMC Bioinformatics.

[52]  U. Holmskov,et al.  Surfactant protein D in atopic dermatitis and psoriasis , 2006, Experimental dermatology.

[53]  Cees G. M. Snoek,et al.  Variable Selection , 2019, Model-Based Clustering and Classification for Data Science.

[54]  D. Gladman,et al.  Psoriatic arthritis: epidemiology, clinical features, course, and outcome , 2005, Annals of the rheumatic diseases.

[55]  H. Williams,et al.  Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. , 2004, The Journal of investigative dermatology.

[56]  A. Ziegler,et al.  Ankylosing spondylitis: a β2m–deposition disease? , 2003 .

[57]  T. Egelrud,et al.  Stratum corneum chymotryptic enzyme in psoriasis , 1999, Archives of Dermatological Research.

[58]  J. Prins,et al.  The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. , 1997, Journal of immunology.

[59]  P. Higgins,et al.  P023 CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENT PERSPECTIVES ON PARTICIPATION IN IBD CLINICAL TRIALS , 2018 .

[60]  A. Stubhaug,et al.  Skin pain and discomfort in psoriasis: an exploratory study of symptom prevalence and characteristics. , 2010, Acta dermato-venereologica.

[61]  E. Ferrannini,et al.  High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. , 2009, Clinical and experimental rheumatology.

[62]  A. Ziegler,et al.  Ankylosing spondylitis: a b 2 m-deposition disease? , 2003 .

[63]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[64]  T. Ittel,et al.  Serum osteocalcin levels in patients with psoriatic arthritis: an extended report , 2000, Rheumatology International.

[65]  V. Wright,et al.  Psoriatic arthritis. , 1983, Clinics in rheumatic diseases.